Overview

* OptimizeRx ( OPRX ) Q3 revenue increased 22% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats estimates, rising to $5.1 mln

* Company raises full-year 2025 guidance, introduces 2026 guidance

* OptimizeRx ( OPRX ) paid off $2 mln in principal from term loan after Q3

Outlook

* Company raises 2025 revenue guidance to $105 mln-$109 mln

* Company introduces 2026 revenue guidance of $118 mln-$124 mln

* Company expects 2025 adjusted EBITDA of $16 mln-$19 mln

Result Drivers

* REVENUE GROWTH - Co attributes 22% yr/yr revenue increase to effective execution and enhanced customer outcomes

* TECHNOLOGY AND PARTNERSHIPS - Market-leading patient identification technologies and expanding partnerships drove results

* LOAN REPAYMENT - Co paid off $2 mln in principal from term loan after Q3, reflecting financial discipline

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $26.10 $23.83

Revenue mln mln (7

Analysts

)

Q3 Beat $3.90 $977,830

Adjusted mln (6

Net Analysts

Income )

Q3 Beat $5.10 $1.86

Adjusted mln mln (7

EBITDA Analysts

)

Q3 Cash $19.50

& mln

Investme

nts

Q3 Gross $17.50

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the online services peer group is "buy"

* Wall Street's median 12-month price target for OptimizeRx Corp ( OPRX ) is $20.00, about 4.2% above its November 5 closing price of $19.16

* The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)